These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22188635)

  • 1. Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.
    Wu L; Rosa-Neto P; Gauthier S
    Mol Diagn Ther; 2011 Dec; 15(6):313-25. PubMed ID: 22188635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.
    Mueller SG; Schuff N; Weiner MW
    NMR Biomed; 2006 Oct; 19(6):655-68. PubMed ID: 16986115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and evolving treatment strategies for the Alzheimer disease continuum.
    Marasco RA
    Am J Manag Care; 2020 Aug; 26(8 Suppl):S167-S176. PubMed ID: 32840330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of biomarkers in clinical trials for Alzheimer disease.
    Thal LJ; Kantarci K; Reiman EM; Klunk WE; Weiner MW; Zetterberg H; Galasko D; Praticò D; Griffin S; Schenk D; Siemers E
    Alzheimer Dis Assoc Disord; 2006; 20(1):6-15. PubMed ID: 16493230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play.
    Jack CR
    Radiology; 2012 May; 263(2):344-61. PubMed ID: 22517954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of family history for Alzheimer biomarker abnormalities in the adult children study.
    Xiong C; Roe CM; Buckles V; Fagan A; Holtzman D; Balota D; Duchek J; Storandt M; Mintun M; Grant E; Snyder AZ; Head D; Benzinger TL; Mettenburg J; Csernansky J; Morris JC
    Arch Neurol; 2011 Oct; 68(10):1313-9. PubMed ID: 21987546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
    Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
    Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.
    Scheinin NM; Scheinin M; Rinne JO
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):265-79. PubMed ID: 21532540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for Alzheimer's disease therapeutic trials.
    Hampel H; Wilcock G; Andrieu S; Aisen P; Blennow K; Broich K; Carrillo M; Fox NC; Frisoni GB; Isaac M; Lovestone S; Nordberg A; Prvulovic D; Sampaio C; Scheltens P; Weiner M; Winblad B; Coley N; Vellas B;
    Prog Neurobiol; 2011 Dec; 95(4):579-93. PubMed ID: 21130138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.